Wells Fargo Biotech Conference Day 1 section 2 - Milestone Pharmaceuticals Inc.

MIST (update): Milestone is launching Cardamyst for at-home treatment of paroxysmal SVT, with encouraging clinician feedback and more than 50% of commercially covered lives now covered through agreements involving major payer groupings, though broader adoption by general cardiologists remains the next hurdle. Launch-year revenue per prescription is intentionally low to get the product into patients’ hands and establish prescribing habits; the larger opportunity is AFib with rapid ventricular response, where Phase 2 showed a ~30 bpm placebo-adjusted reduction and Phase 3 data are targeted for 2H28.

Read full article (1 min)